Core Insights - 4D Molecular Therapeutics is a late-stage biotechnology company focused on developing durable and disease-targeted therapeutics that aim to transform treatment paradigms and provide significant benefits to patients [1][3] Company Overview - The lead product candidate, 4D-150, targets blinding retinal vascular diseases and offers multi-year sustained delivery of anti-VEGF through a single intravitreal injection, reducing the treatment burden compared to current methods [3] - 4D-150 is currently in Phase 3 development for wet age-related macular degeneration and is also being studied for diabetic macular edema [3] - The second product candidate, 4D-710, is the first genetic medicine to successfully deliver and express the CFTR transgene in the lungs of cystic fibrosis patients via aerosol delivery [3] Upcoming Events - Management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on November 18, 2025, at 9:00 a.m. GMT, with one-on-one meetings available [2]